Alzheimer'S Disease Clinical Trials in Cincinnati, OH

Alzheimer'S Disease Clinical Trials in Cincinnati, OH

View the best 10 alzheimer's disease medical studies in Cincinnati, Ohio. Access promising new therapies by applying to a Cincinnati-based Alzheimer'S Disease clinical trial.

Trials in Cincinnati, Ohio

Here are the top 10 medical studies for alzheimer's disease in Cincinnati, Ohio

Image of Ah0003 50423 in East Providence, United States.

Bepranemab

Monoclonal Antibodies

Recruiting0 awardsPhase 2
This trial is testing bepranemab, a new medication, to see if it can help people with early-stage Alzheimer's disease. The study focuses on individuals who are just starting to show symptoms or have mild symptoms. Bepranemab works by removing harmful proteins from the brain that are linked to Alzheimer's.
Image of Clinical Research Site in Toms River, United States.

AXS-05 +1 More

NMDA receptor antagonist

Verified
Recruiting1 awardPhase 3
This trial is testing a new medication called AXS-05 to see if it can help reduce agitation in people with Alzheimer's disease. The goal is to find out if AXS-05 can balance brain chemicals to calm agitation and improve behavior. AXS-05, a combination of dextromethorphan and bupropion, is being investigated for its potential to treat agitation in Alzheimer's disease and has shown promise in early clinical trials.
Image of Rhode Island Mood & Memory Research Institute in East Providence, United States.

Simufilam

Small Molecule

Recruiting2 awardsPhase 3
This trial looks at how safe a drug is over time for people who have already taken it in a previous trial.
Image of Novo Nordisk Investigational Site in Lomita, United States.

Semaglutide

Glucagon-like peptide-1 (GLP-1) receptor agonist

Recruiting1 awardPhase 3
This trial is to test whether the medication semaglutide has a positive effect on early Alzheimer's disease. The study will last for up to 173 weeks, and participants will have 17 clinic visits and 1 phone call with the study doctor. The study includes various tests and scans, and at 10 of the clinic visits participants will have blood samples taken. The trial is only for women.
Image of Center for Cognitive Health in Portland, United States.

ATH-1017

Recruiting1 awardPhase 2 & 3
This trial is testing the safety and tolerability of fosgonimeton in Alzheimer's patients who have completed other studies.
Image of Kingfisher Cooperative in Spokane, United States.

AR1001

Verified
Recruiting1 awardPhase 3
This trial tests AR1001, a medicine for early Alzheimer's Disease. It focuses on people in the early stages of Alzheimer's, aiming to improve their condition through multiple mechanisms.
Image of University of Alabama, Birmingham in Birmingham, United States.

Lecanemab +1 More

Monoclonal Antibodies

Recruiting1 awardPhase 3
This trial is testing lecanemab, a drug aimed at improving memory and thinking skills in people with early signs of Alzheimer's disease. The drug works by reducing amyloid plaques in the brain, which are believed to contribute to Alzheimer's. Researchers want to see if lecanemab is effective over several years.
Image of ATP Clinical Research, Inc. in Costa Mesa, United States.

Masupirdine

Behavioural Intervention

Recruiting1 awardPhase 3
This trial will test a medication called masupirdine, which participants will take regularly. It targets people with Alzheimer's disease who are experiencing agitation. The study aims to see if masupirdine can help reduce agitation and ensure it is safe and well-tolerated. Masupirdine has been previously evaluated in patients with moderate Alzheimer's disease and was found to be generally safe and well-tolerated.
Image of Valley Clinical Trials, Inc. in Covina, United States.

Donanemab

Monoclonal Antibodies

Verified
Recruiting1 awardPhase 3
This trial is testing donanemab, a medication aimed at helping people with Alzheimer's Disease by removing harmful protein clumps from their brains. Donanemab has shown promise in reducing these harmful proteins in Alzheimer's disease.
Image of IU Health in Indianapolis, United States.

Brain CareNotes

Behavioural Intervention

Recruiting1 award
This trial tests if the Brain CareNotes app can reduce stress for unpaid caregivers of dementia patients and improve patient symptoms. The app provides practical advice, reminders, and emotional support to help caregivers manage their tasks.

Phase 3 Trials

Trials With No Placebo

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.